Evaluation of tofacitinib in cutaneous sarcoidosis [Olink Explore 1536]

ABSTRACT: Sarcoidosis is a multisystem inflammatory disease and no molecularly targeted therapies exist. Here we evaluate the efficacy of tofacitinib (a JAK1/3 inhibitor) in an open-label trial of 10 patients with sarcoidosis and correlate clinical improvement with molecular parameters in blood and skin.

ORGANISM(S): Homo sapiens

PROVIDER: GSE169148 | GEO | 2022/03/30

REPOSITORIES: GEO